Last reviewed · How we verify
Pranlukast hydrate
Pranlukast hydrate is a leukotriene receptor antagonist that inhibits the action of leukotrienes, which are involved in the inflammatory process.
Pranlukast hydrate is a leukotriene receptor antagonist that inhibits the action of leukotrienes, which are involved in the inflammatory process. Used for Asthma.
At a glance
| Generic name | Pranlukast hydrate |
|---|---|
| Sponsor | SamA Pharmaceutical Co., Ltd |
| Drug class | Leukotriene receptor antagonist |
| Target | CysLT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Leukotrienes are pro-inflammatory mediators that play a key role in the pathogenesis of asthma and other inflammatory diseases. By blocking the action of leukotrienes, pranlukast hydrate reduces inflammation and improves symptoms in patients with asthma.
Approved indications
- Asthma
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects (PHASE1)
- Study of ONO-1078 in Patients With Chronic Sinusitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pranlukast hydrate CI brief — competitive landscape report
- Pranlukast hydrate updates RSS · CI watch RSS
- SamA Pharmaceutical Co., Ltd portfolio CI